Moderna’s RNA vaccine latest development
US-based Modera Inc has already successfully finished its stage 1 of clinal trials and is among the leading candidates in the development of a possible vaccine for the novel coronavirus.
The Massachusetts-based biotech company is developing an RNA-based vaccine and is all set to begin phase 2 of its clinical trials for the same on 600 healthy individuals.
The mRNA vaccine (mRNA-1273) has already shown promising results in developing protective antibodies against the virus.A smallscale trial of Moderna’s RNA-based vaccine was conducted in the month of March, where 8 individuals of the 45 who were given the trial vaccine developed protective antibodies.
All the 45 participants were given 25-250 mcg dosage of the vaccine, while the eight individuals who developed protective antibodies were injected with 25 and 100 mcg dose of the vaccine.
Moderna’s vaccine side-effects
While initially, only minor side-effects were observed in the individuals including chills, local pain, soreness and redness at the site of injection, a volunteer has reported a severe reaction to Moderna vaccine.
The Patanjali group vaccine
Ramdev’s Patanjali group has also joined the global efforts of developing a vaccine for the novel coronavirus. The group is known for its ayurvedic based supplements and products and is all set to conduct clinical trials after securing permission from regulatory authorities. The clinical trials will begin in Indore and Jaipur.